Table 1.
Summary of Patient Data: Medications and Laboratory Values
| Months 0–40 | Months 42–44 | Month 45 | Month 47 | Month 48 | Month 49 | Month 50 | Month 52a | Month 54 | Month 56 | Month 62 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Key medications | Glyburide | Insulin | Insulin | Glyburide and dapsone started March 2013 | Glyburide and metformin, dapsone | Glyburide and metformin, dapsone | Glyburide and metformin, dapsone | Metformin, dapsone (glyburide stopped for <1 week) | Glyburide and metformin, NO dapsone | Glyburide and metformin, septra SS, NO dapsone | Glyburide and metformin, insulin, septra SS, NO dapsone |
| Fructosamine (range, 190–270 μmol/L) | 407 | 392 | |||||||||
| Glucose (range, 70–99 mg/dL) | 120–150 (fasting) | 80–140 (fasting) | 100–160 (fasting) | 120–150 (fasting) and 200 (pre-dinner) | 120–150 (fasting) and 200 (pre- dinner) | 166–184 (fasting) and 271–285 (pre- dinner) | 110–140 (fasting) and 160–200 (pre-dinner) | 110–154 (fasting) | |||
| Hemoglobin A1c (range, 4.3–5.6%) | 7.0–8.3 | 7.1 | 4.9 | 4.8 | 5.2 | 4.6 | 4.2 | 6.8 | 7.8 | 7.0 |
a
Dapsone was stopped after month 52 and has not been restarted since.